Daxor Corporation 10-K Summary: Fiscal Year Ended December 31, 2003
Business Context and Reporting Period
Daxor Corporation is a medical device manufacturer and biotech service provider reporting for the fiscal year ended December 31, 2003. The Company's primary focus is the BVA-100(TM) Blood Volume Analyzer, an instrument designed to rapidly and accurately measure human blood volume, alongside its subsidiary, Scientific Medical Systems (Idant), which operates blood and semen banking services. The Company holds U.S., European, and Japanese patents for its blood volume analysis technology.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Total Revenues | $3,165,437 | $2,701,937 |
| Operating Revenues | $1,013,647 | $767,608 |
| Dividend Income | $1,897,669 | $1,858,025 |
| Gains on Sale of Investments | $238,550 | $40,610 |
| Net Loss | $(1,076,189) | $(193,851) |
| Net Loss Per Share | $(0.23) | $(0.04) |
| Total Assets | $48,300,532 | $41,573,565 |
| Shareholders' Equity | $36,417,170 | $33,546,897 |
| Short-Term Debt | $2,502,106 | $1,434,046 |
| Working Capital | $36,044,529 | $33,136,421 |
| Market Value of Securities Portfolio | $47,399,159 | $40,573,162 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 17% to $3.17 million, driven by a 32% increase in operating revenues ($1.01 million) and a significant rise in gains on the sale of investments ($238,550 vs. $40,610).
- Expense Surge: Total costs and expenses rose 47% to $4.22 million. This was primarily due to increased hiring of sales and marketing personnel and expanded marketing efforts for the BVA-100.
- Widened Loss: The net loss expanded significantly from $193,851 in 2002 to $1,076,189 in 2003 as operating expenses outpaced revenue growth.
- Debt Increase: Short-term debt increased by approximately $1.07 million to $2.5 million, consisting of bank loans and margin debt secured by marketable securities.
- Portfolio Appreciation: The Company's investment portfolio, primarily utility stocks, appreciated in market value by roughly $6.8 million, contributing to a strong balance sheet despite operating losses.
Guidance, Outlook, and Risks
Outlook and Strategy: Management anticipates that the BVA-100 will become the primary revenue source, targeting a potential market of 15-20 million tests annually. The Company is aggressively expanding its sales force (now 11 sales staff plus support) and marketing efforts. Management expects operating expenses to continue rising faster than revenues in the near term to achieve market penetration.
Liquidity: The Company maintains a conservative liquidity policy, relying on its diversified securities portfolio to fund operations and growth without immediate need for external capital. Management believes current assets are sufficient to sustain the expanded marketing program for the next 2 to 4 years.
Risks and Contingencies:
- Market Acceptance: Success depends on demonstrating the cost-effectiveness and clinical necessity of blood volume measurement to hospitals and HMOs.
- Regulatory: Operations are subject to FDA regulation for medical devices and New York State Department of Health regulation for banking services.
- Investment Risk: A significant portion of revenue and asset value is tied to the performance of the utility sector and the Company's investment portfolio.
- Legal: Several claims are pending, though management believes they lack merit and will not materially affect financial statements.
Investor Verification Checklist
- Verify the sustainability of the investment portfolio's unrealized gains ($25.4 million) and their impact on the balance sheet under FASB No. 115.
- Confirm the rate of BVA-100 unit sales and lease agreements to validate the 32% increase in operating revenues.
- Assess the burn rate of cash given the 47% increase in operating expenses and the widening net loss.
- Review the terms of the short-term margin debt ($1.6 million) and bank loans ($900,000) secured by the securities portfolio.
- Monitor the progress of clinical studies (e.g., Cleveland Clinic, Mayo Clinic) cited as evidence for the device's efficacy and market potential.